Immune Globulins for Post-Exposure Prophylaxis
Aetna clinical policy bulletin defining medical necessity criteria, continuation criteria, precertification requirements, dosing guidance, and applicable billing codes for various immune globulin products used for post-exposure prophylaxis and treatment (e.g., hepatitis A/B, CMV, Rho-D, rabies, varicella, tetanus, vaccinia, infantile botulism, IGIM/GamaSTAN). This part (1 of 3) includes policy statements, continuation rules, dosing/administration for IGIM, FDA indications/limitations, background and related evidence, and extensive CPT/HCPCS/ICD-10 code lists.
No material clinical or coverage changes in this update.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.